

16th December 2024

Drug Discontinuation

Discontinuation of Protaphane[®] InnoLet[®]

Dear Valued Client,

Further to DrugAlert [vol 966](#), HPS Pharmacies wishes to advise that Novo Nordisk is discontinuing the following insulin product:

Protaphane[®] InnoLet[®], 3mL
Human insulin 100 units/mL
ARTG 169633

Protaphane[®] InnoLet[®] is due to be deleted from the market on 1st February 2025.

The *Therapeutic Goods Administration* (TGA) has implemented a [Serious Scarcity Substitution Instrument](#) (SSSI) to help manage this situation. The SSSI allows pharmacists to supply Protaphane[®] Penfill (100 units/mL) 3mL cartridges, providing the conditions of the SSSI are met, including:

- Patient is provided with a suitable insulin delivery system to administer their medication; and
- Patient or person acting on their behalf is educated on the differences between the presentations and how to correctly administer the substituted medicine.

This SSSI is in force until 28 February 2026, unless revoked earlier by the TGA. Further information can be found on the [TGA website](#). Information on *Pharmaceutical Benefits Scheme* (PBS) subsidy arrangements for medicines substituted using an SSSI can be found on the [PBS website](#).

Retain this notice in a prominent position, including in other related business units for at least one month. Report any problems identified with medicines, vaccines or medical devices to the [TGA](#).

Should you require further information regarding this matter, please contact Novo Nordisk on 1800 668 626 or your pharmacist at [HPS Pharmacies](#).

Kind regards,
Sallie Drake BPharm Clinical Communications Coordinator, HPS
e sallie.drake@hps.com.au
www.hps.com.au